informed consent
Item
1. patients must have signed an irb approved informed consent.
boolean
C0021430 (UMLS CUI [1])
adenocarcinoma of the colon or rectum
Item
2. patients with histologically or pathologically documented, stage iiib or iv adenocarcinoma of the colon or rectum.
boolean
C0011900 (UMLS CUI [1])
C0338106 (UMLS CUI [2])
C0149978 (UMLS CUI [3])
inoperable disease
Item
3. patients with disease that is not amenable to potentially curative resection (i.e., inoperable metastatic disease).
boolean
C0006826 (UMLS CUI [1,1])
C0205187 (UMLS CUI [1,2])
egfr
Item
4. patients with tumors that are egfr + by ihc staining.
boolean
C0034802 (UMLS CUI [1,1])
C0021044 (UMLS CUI [1,2])
ecog performance status
Item
5. patients with ecog performance status of 0 or 1.
boolean
C1520224 (UMLS CUI [1])
age, pregnancy, sterile, postmenopausal
Item
6. patients, 18 years and older, must either be not of child bearing potential or have a negative serum pregnancy test within 7 days prior to registration. patients are considered not of child bearing potential if they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or they are postmenopausal.
boolean
C0001779 (UMLS CUI [1])
C0032961 (UMLS CUI [2])
C0021359 (UMLS CUI [3])
C0232970 (UMLS CUI [4])
bone marrow function, neutrophil count, platelets
Item
7. bone marrow function: absolute neutrophil count (anc) > or = 1,500/ul, equivalent to common terminology criteria for adverse events (ctcae, version 3) grade 1. platelets > or = 100,000/ul (ctcae grade 0 - 1).
boolean
C0200633 (UMLS CUI [1])
C0005821 (UMLS CUI [2])
creatinine
Item
8. renal function: creatinine < or = 1.5 x institutional upper limit of normal (uln), ctcae grade 1.
boolean
C0201976 (UMLS CUI [1])
bilirubin
Item
9. hepatic function: bilirubin < or = 1.5 x uln, ctcae grade 1. ast < or = 2.5 x uln, ctcae grade 1.
boolean
C1278039 (UMLS CUI [1])
prior chemotherapy
Item
1. patients who received prior chemotherapy for metastatic disease. prior adjuvant therapy with 5fu/lv and/or irinotecan is allowed provided it was completed at least 6 months prior to enrollment in this study.
boolean
C1514457 (UMLS CUI [1])
oxaliplatin
Item
2. patents who received prior oxaliplatin.
boolean
C0069717 (UMLS CUI [1,1])
C1514457 (UMLS CUI [1,2])
cetuximab
Item
3. patients who received prior cetuximab or other therapy which specifically and directly targets the egf pathway.
boolean
C0995188 (UMLS CUI [1,1])
C1514457 (UMLS CUI [1,2])
acute hepatitis
Item
4. patients with acute hepatitis.
boolean
C0267797 (UMLS CUI [1])
active or uncontrolled infection
Item
5. patients with active or uncontrolled infection.
boolean
C0009450 (UMLS CUI [1,1])
C0205177 (UMLS CUI [1,2])
C0009450 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
cardiac disease, uncontrolled hypertension, unstable angina, and congestive heart failure
Item
6. patients with a significant history of cardiac disease, i.e., uncontrolled hypertension, unstable angina, and congestive heart failure.
boolean
C0018799 (UMLS CUI [1])
C1868885 (UMLS CUI [2])
C0002965 (UMLS CUI [3])
C0018802 (UMLS CUI [4])
allergic reaction to chimerized or murine monoclonal antibody therapy
Item
7. prior allergic reaction to chimerized or murine monoclonal antibody therapy.
boolean
C1527304 (UMLS CUI [1,1])
C0003250 (UMLS CUI [1,2])
concurrent chemotherapy or any other investigational agent
Item
8. any concurrent chemotherapy not indicated in the study protocol or any other investigational agent.
boolean
C0392920 (UMLS CUI [1,1])
C0205420 (UMLS CUI [1,2])
C0013230 (UMLS CUI [2])
peripheral neuropathy
Item
9. patients with peripheral neuropathy > grade 1
boolean
C0031117 (UMLS CUI [1])